slides · global inventory
All filtered slides
Global slide inventory for the active corpus filters, with each row opening the slide detail view.
Corpus coverage
319,975 slides
319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.
- Total slides
- 319,975
- Described
- 319,974
- Pending
- 1
100%ready for canon
Slide type composition
dynamicclickable
Slide type
Showing 319,974 described slides — 100.0% of 319,975 rendered pages
+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs
Tile area is proportional to slide count. Click a category to open its subtype map.
all document kinds · all orientations
Slide collection
232,411-232,440 of 319,975
04
The slide combines team bios with business model and partnership validation.BenevolentAI | Investor Presentation Deck | 31 slides · BenevolentAI
Pitch deck Investor relations 1 hit
05
Uses a structured layout to categorize problems into three pillars: cost/risk, time, and efficacy.BenevolentAI | Investor Presentation Deck | 31 slides · BenevolentAI
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
06
BenevolentAI | Investor Presentation Deck | 31 slidesBenevolentAI | Investor Presentation Deck | 31 slides · BenevolentAI
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Golden Circle1 hit
07
The slide uses a split-screen layout to contrast partnership-based revenue with internal pipeline development.BenevolentAI | Investor Presentation Deck | 31 slides · BenevolentAI
Pitch deck Investor relations 1 hit
08
The slide uses a process flow diagram to illustrate the drug discovery pipeline.BenevolentAI | Investor Presentation Deck | 31 slides · BenevolentAI
Pitch deck Investor relations 1 hit
09
The slide uses a circular arrow graphic to represent a feedback loop between in-silico and in-vitro processes.BenevolentAI | Investor Presentation Deck | 31 slides · BenevolentAI
Pitch deck Investor relations 1 hit
10
The slide uses a 'How we did it' process flow at the bottom to explain the underlying methodology.BenevolentAI | Investor Presentation Deck | 31 slides · BenevolentAI
Pitch deck Investor relations 1 hit
11
The slide uses a timeline on the left and a summary of partnership terms on the right.BenevolentAI | Investor Presentation Deck | 31 slides · BenevolentAI
Pitch deck Investor relations 1 hit
12
BenevolentAI | Investor Presentation Deck | 31 slidesBenevolentAI | Investor Presentation Deck | 31 slides · BenevolentAI
Pitch deck Investor relations 1 hit
13
The slide uses a Gantt-style chart to show the progress of different drug programs. It distinguishes between proprietary (teal) and partner (yellow) pipelines.BenevolentAI | Investor Presentation Deck | 31 slides · BenevolentAI
Pitch deck Investor relations 1 hit
14
Includes two process diagrams illustrating the Benevolent Platform's role and the experimental validation process.BenevolentAI | Investor Presentation Deck | 31 slides · BenevolentAI
Pitch deck Investor relations 1 hit
15
The slide uses a table to demonstrate market validation for early-stage IBD assets.BenevolentAI | Investor Presentation Deck | 31 slides · BenevolentAI
Pitch deck Investor relations Beat · Market Size1 hit
16
The slide uses a causal chain logic to connect market deal activity and clinical unmet needs to the value proposition of the drug.BenevolentAI | Investor Presentation Deck | 31 slides · BenevolentAI
Pitch deck Investor relations Loop · Why Now1 hit
17
The slide uses a two-row structure to contrast 'Collaborations' and 'Out licensing' business models.BenevolentAI | Investor Presentation Deck | 31 slides · BenevolentAI
Pitch deck Investor relations 1 hit
18
The slide uses a grid layout to present three distinct partner endorsements with associated logos and investment figures.BenevolentAI | Investor Presentation Deck | 31 slides · BenevolentAI
Pitch deck Investor relations 1 hit
19
The slide uses a grid layout to present financial KPIs.BenevolentAI | Investor Presentation Deck | 31 slides · BenevolentAI
Pitch deck Investor relations Beat · Financials1 hit
20
The slide uses a vertical list format to present the investment thesis.BenevolentAI | Investor Presentation Deck | 31 slides · BenevolentAI
Pitch deck Investor relations 1 hit
21
BenevolentAI | Investor Presentation Deck | 31 slidesBenevolentAI | Investor Presentation Deck | 31 slides · BenevolentAI
Pitch deck Investor relations 1 hit
22
Includes corporate structure details, shareholder list, and headshots of leadership.BenevolentAI | Investor Presentation Deck | 31 slides · BenevolentAI
Pitch deck Investor relations 1 hit
23
Includes a reference to Eroom's law, which describes the observation that drug discovery is becoming slower and more expensive over time.BenevolentAI | Investor Presentation Deck | 31 slides · BenevolentAI
Pitch deck Investor relations Beat · Agitate (Make it worse)1 hit
24
The slide uses a split-screen approach to contrast two distinct value drivers: cost reduction and success rate improvement.BenevolentAI | Investor Presentation Deck | 31 slides · BenevolentAI
Pitch deck Investor relations 1 hit
25
The slide uses a table format to demonstrate differentiation and market potential for five specific pipeline assets.BenevolentAI | Investor Presentation Deck | 31 slides · BenevolentAI
Pitch deck Investor relations 1 hit
26
The slide outlines a standard clinical trial structure (SAD, Food Effect, MAD) and highlights the competitive advantage of a clean safety profile compared to historical PDE10 inhibitors.BenevolentAI | Investor Presentation Deck | 31 slides · BenevolentAI
Pitch deck Investor relations 1 hit
27
The slide emphasizes the absence of CNS-associated adverse events, which is a key differentiator for this PDE10 inhibitor.BenevolentAI | Investor Presentation Deck | 31 slides · BenevolentAI
Pitch deck Investor relations 1 hit
28
The slide uses a combination of text, scientific charts (dose-response curves), and a process diagram to validate the drug's mechanism.BenevolentAI | Investor Presentation Deck | 31 slides · BenevolentAI
Pitch deck Investor relations 1 hit
29
The slide uses a honeycomb/network diagram to represent data integration and processing.BenevolentAI | Investor Presentation Deck | 31 slides · BenevolentAI
Pitch deck Investor relations 1 hit
30
The slide uses a process flow diagram to map specific technical capabilities to stages of drug discovery.BenevolentAI | Investor Presentation Deck | 31 slides · BenevolentAI
Pitch deck Investor relations 1 hit
31
The slide uses a three-column layout to categorize value drivers: proprietary pipeline, partnerships, and future growth.BenevolentAI | Investor Presentation Deck | 31 slides · BenevolentAI
Pitch deck Investor relations 1 hit
01
Delivery Hero | Investor Presentation Deck | 54 slidesDelivery Hero | Investor Presentation Deck | 54 slides · Delivery Hero
Conference presentation Investor relations 1 hit
02
Delivery Hero | Investor Presentation Deck | 54 slidesDelivery Hero | Investor Presentation Deck | 54 slides · Delivery Hero
Conference presentation Investor relations 1 hit